Lotus Eye Hospital And Institute Share Price & Stock Analysis

Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 198

Key Metrics

Current Price₹108.37
Market Cap₹225 Cr
SectorHealth Care > Health Care Equipment and Services > Health Care Providers and Services
Sub-IndustryHealth Care Facilities > Hospitals and Healthcare Centers
P/E Ratio301
Return on Equity1.24%
52-Week Range₹67.72 – ₹147.00
Beta (1Y)0.21
Dividend Yield0.00%

Business Segments

1. Providing Health Care (Eye Care) Services-100%

Peer Companies

Frequently Asked Questions

What is the current share price of Lotus Eye Hospital And Institute?

Lotus Eye Hospital And Institute is trading at ₹108.37, with a market capitalisation of ₹225 Cr.

Which sector does Lotus Eye Hospital And Institute belong to?

Lotus Eye Hospital And Institute operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).

What are the key financial ratios of Lotus Eye Hospital And Institute?

Lotus Eye Hospital And Institute has a P/E of 301 and a return on equity of 1.24%.